SCHEMBL2279693

SCHEMBL2279693

CN(C)C(=O)COc1cccc(C=O)c1

nearest known ligand 0.55

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.55
MAOA P21397 7/20 0.51
MAOB P27338 7/20 0.51
NPC1 O15118 3/20 0.50
RAB9A P51151 3/20 0.50
TDP1 Q9NUW8 1/20 0.50
KDM4E B2RXH2 2/20 0.48
ALDH1A1 P00352 2/20 0.48
TP53 P04637 1/20 0.47
HPGD P15428 1/20 0.47
HSD17B10 Q99714 1/20 0.47
SRC P12931 1/20 0.46
KEAP1 Q14145 2/20 0.45
NFE2L2 Q16236 2/20 0.45
PDK2 Q15119 1/20 0.44
LMNA P02545 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2281419 0.83 MAOA (0.55) SMN1; SMN2MAOAMAOBNPC1RAB9A
SCHEMBL385690 0.82 PPARA (0.58) SMN1; SMN2MAOAMAOBNPC1RAB9A
SCHEMBL353914 0.81 MAOA (0.61) MAOAMAOBNPC1RAB9ATDP1
SCHEMBL6538464 0.81 SMN1; SMN2 (0.61) SMN1; SMN2NPC1RAB9AKDM4EALDH1A1
SCHEMBL1959473 0.80 CYSLTR2 (0.57) MAOAMAOBNPC1RAB9ATDP1
SCHEMBL2285133 0.80 MAOA (0.55) SMN1; SMN2MAOAMAOBNPC1RAB9A
SCHEMBL1955902 0.80 SMN1; SMN2 (0.59) SMN1; SMN2NPC1RAB9AKDM4EALDH1A1
SCHEMBL791810 0.80 LMNA (0.68) SMN1; SMN2NPC1RAB9ATDP1KDM4E
SCHEMBL17710816 0.80 MAOA (0.55) SMN1; SMN2MAOAMAOBNPC1RAB9A
SCHEMBL12217570 0.80 SMN1; SMN2 (0.59) SMN1; SMN2RAB9ATDP1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7989478-B2 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-08-02 US disclosed
US-20060211680-A1 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2006-09-21 US disclosed
EP-1671948-A1 CINNAMOYL COMPOUND AND USE OF THE SAME Sumitomo Chemical Company, Limited (JP) 2006-06-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211680-A1 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis COL2A1, COL1A1, COL14A1 SMN1; SMN2 3766/4885MAOA 3666/4885MAOB 3699/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.